Zerres K, Mücher G, Becker J, Steinkamm C, Rudnik-Schöneborn S, Heikkilä P, Rapola J, Salonen R, Germino G G, Onuchic L, Somlo S, Avner E D, Harman L A, Stockwin J M, Guay-Woodford L M
Institute for Human Genetics, University of Bonn, Germany.
Am J Med Genet. 1998 Mar 5;76(2):137-44.
Autosomal recessive polycystic kidney disease (ARPKD) is one of the most common hereditary renal cystic diseases and has a high infant mortality. Prenatal diagnosis using fetal sonography can be unreliable, especially in early pregnancy. The ARPKD locus has been mapped to proximal chromosome 6p allowing haplotype-based prenatal diagnosis in "at-risk" families. From December 1994 to March 1997, we received 258 inquiries regarding prenatal evaluation and we have completed analyses in 212 families. To date, 65 prenatal analyses have been performed in 57 families. In the majority of the requesting families (45/57), the index children are deceased and their DNA was extracted from paraffin-embedded tissue. Eighteen fetuses were homozygous for the disease-associated haplotypes. In 12 of these fetuses, pathoanatomical examination demonstrated typical ARPKD changes consisting of dilated collecting ducts and the characteristic hepatic ductal plate malformation. These changes were detected in two fetuses as early as 13 weeks gestational age. These cases represent the earliest demonstration of ARPKD-associated histopathology reported to date. One high risk fetus was carried to term and turned out to be unaffected. However, the diagnosis of ARPKD remained doubtful in the index patient. Forty-three fetuses were either heterozygous or homozygous for a nondisease-associated haplotype and all infants born were phenotypically unaffected at birth. In four cases, a recombination event occurred between the flanking markers and no genotypic prediction was possible. Three of these pregnancies were terminated and necropsy of the fetuses confirmed ARPKD, while one fetus was carried to term and showed no abnormalities at birth. These results show that haplotype-based prenatal testing is feasible and reliable in pregnancies "at risk" for ARPKD. An absolute prerequisite for these studies is an accurate diagnosis of ARPKD in previously affected sib(s).
常染色体隐性多囊肾病(ARPKD)是最常见的遗传性肾囊性疾病之一,婴儿死亡率很高。使用胎儿超声进行产前诊断可能不可靠,尤其是在孕早期。ARPKD基因座已被定位到近端6号染色体p区,这使得在“高危”家庭中基于单倍型的产前诊断成为可能。从1994年12月到1997年3月,我们收到了258例关于产前评估的咨询,并且已经完成了对212个家庭的分析。迄今为止,已对57个家庭中的65例进行了产前分析。在大多数咨询家庭(45/57)中,索引儿童已经死亡,他们的DNA是从石蜡包埋组织中提取的。18例胎儿为疾病相关单倍型纯合子。在其中12例胎儿中,病理解剖检查显示出典型的ARPKD变化,包括集合管扩张和特征性的肝导管板畸形。这些变化在孕龄13周的2例胎儿中就已被检测到。这些病例是迄今为止报道的ARPKD相关组织病理学的最早例证。1例高危胎儿足月出生,结果未受影响。然而,索引患者中ARPKD的诊断仍存疑问。43例胎儿为非疾病相关单倍型的杂合子或纯合子,所有出生的婴儿出生时表型均未受影响。在4例中,侧翼标记之间发生了重组事件,无法进行基因型预测。其中3例妊娠终止,胎儿尸检证实为ARPKD,而1例胎儿足月出生,出生时未显示异常。这些结果表明,基于单倍型的产前检测在ARPKD“高危”妊娠中是可行且可靠的。这些研究的一个绝对前提是对先前患病同胞中ARPKD的准确诊断。